Cookies are essential for the operation of our website. By using our website, you agree to the use of cookies.
This website uses cookies to improve and personalize content, and for tracking and analytics. By clicking "Accept All Cookies", you are providing consent for Exelixis to collect and retain personal data for Exelixis to optimize the use of this website. You can learn more about Exelixis' use of cookies by reviewing Exelixis' Privacy Statement.
Reject Nonessential Cookies Accept All Cookies
Skip to main content
Click to go back to the Pipeline page Back To Explore Our Pipeline

Disable motion

XL114: CBM Inhibitor

XL114 is a novel oral anti-cancer compound that inhibits the CARD11-BCL10-MALT1 (CBM) signaling pathway. XL114 is currently being investigated for non-Hodgkin's lymphoma.
XL114 covalently and irreversibly inhibits constitutive activation of the CBM signaling pathway, which is involved in proliferation and survival of malignant B- and T-cells.
Phase 1 dose-escalation and expansion study of XL114 in non-Hodgkin's lymphoma
Cohort Expansions
For more information, visit
clinicaltrials.gov/NCT05144347.
This website includes information on investigational uses of compounds that have not been approved by FDA. Safety and efficacy of investigational compounds and/or investigational uses of approved products have not been established. The information presented should not be construed as a recommendation for use.
Explore All
Pipeline Clinical Trials
Click to go to Resource